BioSpace

Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease

Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.

By BioSpace

1 min read
Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights